Milestone Pharmaceuticals (MIST) to Release Quarterly Earnings on Monday

Milestone Pharmaceuticals (NASDAQ:MIST) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $1.11 on Friday. The stock’s 50 day moving average is $1.33 and its two-hundred day moving average is $1.71. Milestone Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $2.75. The firm has a market capitalization of $59.35 million, a PE ratio of -1.37 and a beta of 0.86. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18.

Wall Street Analyst Weigh In

MIST has been the topic of a number of recent analyst reports. Cowen cut shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. TD Cowen cut Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 1st. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. Finally, TD Securities downgraded shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.